PMID- 26605555
OWN - NLM
STAT- MEDLINE
DCOM- 20160526
LR  - 20160120
IS  - 1827-1669 (Electronic)
IS  - 0026-4806 (Linking)
VI  - 106
IP  - 6
DP  - 2015 Dec
TI  - Cell therapy for bone nonunion: a retrospective study.
PG  - 315-21
AB  - AIM: The aim of this study was to report our experience in augmenting nonunion 
      both with bone marrow mononuclear cells/mesenchymal stem cells (MSCs) and 
      conventional surgical approaches; and for clinical applications, a simple, safe, 
      and reproducible method to effectively treat bone mass loss disease. METHODS: A 
      retrospective analysis was performed on stem cell-treated bone nonunion patients 
      from October 1, 2007 to October 1, 2009. Nine patients were categorized into two 
      groups: group 1 consists of 3 patients who received autologous bone marrow 
      mononuclear cells transplantation; group 2 consists of 6 patients who received 
      umbilical cord MSCs (hUC-MSCs) transplantation. All patients accepted 
      conventional surgical treatment and X-ray supervised at 3, 6, and 12 months or so 
      after transplantation, while T cells' subtype was analyzed. RESULTS: All patients 
      were followed up for 36 months through recheck Out-patient Department and X-ray 
      examination to observe the fracture healing. The mean time for clinical healing 
      was comparable in both groups. The mean time of fracture lines blurred partly, 
      continuous bone callus formation, marrow flow was 3.5M, 6.2M, and 9.1M, 
      respectively, in the human umbilical cord mesenchymal stem cells (hUC-MSCs) 
      treatment group. The compared healing times were 3.8 M, 7.1M and 10.6 months in 
      autologous bone marrow mononuclear cells transplantation, respectively. The serum 
      levels of CD4, CD56, and HLA-DR in hUC-MSCs graft group were negative, while the 
      serum level of CD8 was 7.8% positive. Clearly, there was no significant 
      difference in the percent of T subsets between the 2 groups of T cells' subtype. 
      CONCLUSION: Our study showed that patients treated by allograft-augmentation had 
      no complications, reduced treatment- dissatisfaction. The use of hUC-MSCs should 
      be offered to suitable patients in the preoperative consultation as a valuable 
      alternative for autologous grafting and larger clinical trials should be 
      considered in the future.
FAU - Qu, Z
AU  - Qu Z
AD  - Department of Orthopedic Surgery, Siping Hospital of China Medical University, 
      Siping, Jilin, China - ly3641829@163.com.
FAU - Fang, G
AU  - Fang G
FAU - Cui, Z
AU  - Cui Z
FAU - Liu, Y
AU  - Liu Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20151125
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
MH  - Adult
MH  - Bone Marrow Cells
MH  - *Cell- and Tissue-Based Therapy/methods
MH  - *Cord Blood Stem Cell Transplantation
MH  - Female
MH  - Follow-Up Studies
MH  - Fracture Healing
MH  - Fractures, Ununited/pathology/*therapy
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Middle Aged
MH  - Monocytes/*transplantation
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
EDAT- 2015/11/26 06:00
MHDA- 2016/05/27 06:00
CRDT- 2015/11/26 06:00
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/05/27 06:00 [medline]
AID - R10Y9999N00A150028 [pii]
PST - ppublish
SO  - Minerva Med. 2015 Dec;106(6):315-21. Epub 2015 Nov 25.